2-[2-methoxy-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-yl)methyl]phenoxy]-N-(4-methoxyphenyl)acetamide | 1224637-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[2-methoxy-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-yl)methyl]phenoxy]-N-(4-methoxyphenyl)acetamide
• CAS: 1224637-18-6
• 化学式: C₂₀H₂₀N₂O₅S₂
• 分子量: 432.521
• InChiKey: KYGZCJFHRFLYRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-[2-methoxy-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]phenoxy]-N-(4-methoxyphenyl)acetamide 在 5% Pd(II)/C(eggshell) 、 氢气 、 溶剂黄146 作用下， 反应 14.0h， 生成 2-[2-methoxy-4-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-yl)methyl]phenoxy]-N-(4-methoxyphenyl)acetamide
  参考文献：
  名称：

  Novel glitazones: Design, synthesis, glucose uptake and structure–activity relationships

  摘要：

  Glitazones are known to exhibit antihyperglycemic activity by decreasing peripheral insulin resistance. In the present study, we have designed some novel glitazones based on the structure-activity relationships as possible PPAR-gamma agonists. The manually designed glitazones were synthesized by using the appropriate synthetic schemes and screened for their in vitro antihyperglycemic activity by estimating glucose uptake by rat hemi-diaphragm, both in the absence and in the presence of external insulin. Some of the glitazones exhibited good antihyperglycemic activity in presence of insulin. Illustration about their design, synthesis, evaluation, and structure-activity relationships is described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.125

文献信息

• Novel glitazones: Design, synthesis, glucose uptake and structure–activity relationships
  作者：B.R. Prashantha Kumar、M.J. Nanjan

  DOI：10.1016/j.bmcl.2010.01.125

  日期：2010.3

  Glitazones are known to exhibit antihyperglycemic activity by decreasing peripheral insulin resistance. In the present study, we have designed some novel glitazones based on the structure-activity relationships as possible PPAR-gamma agonists. The manually designed glitazones were synthesized by using the appropriate synthetic schemes and screened for their in vitro antihyperglycemic activity by estimating glucose uptake by rat hemi-diaphragm, both in the absence and in the presence of external insulin. Some of the glitazones exhibited good antihyperglycemic activity in presence of insulin. Illustration about their design, synthesis, evaluation, and structure-activity relationships is described. (C) 2010 Elsevier Ltd. All rights reserved.